The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 263-272

  Kaiser, Martin F ^a   Heider, Ulrike ^a   Mieth, Maren ^a   Zang, Chuanbing ^a   von Metzler, Ivana ^a   Sezer, Orhan ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bortezomib; Mesenchymal stem cell; Multiple myeloma; Osteoblast; Proteasome; Vitamin D receptor

Indexed keywords

BORTEZOMIB; OSTEOCALCIN; OSTEOPONTIN; VITAMIN D RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL VIABILITY; COCULTURE; CONCENTRATION (PARAMETERS); DOWN REGULATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MYELOMA; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VITAMIN D DEFICIENCY;

BASE SEQUENCE; BORONIC ACIDS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOPONTIN; PROTEASOME INHIBITORS; PYRAZINES; RECEPTORS, CALCITRIOL; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION; VITAMIN D DEFICIENCY;

EID: 84875260832     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12069     Document Type: Article

References (42)

1. Kyle RA, Rajkumar SV Multiple myeloma. N Engl J Med 2004;351:1860-73.
2. Rajkumar SV, Kyle RA, Gertz MA Myeloma and the newly diagnosed patient: a focus on treatment and management. Semin Oncol 2002;29:5-10.
3. Lentzsch S, Ehrlich LA, Roodman GD Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007;21:1035-49, viii.
4. Sezer O Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009;14:276-83.
5. Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700-12.
6. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005;338:687-93.
7. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-4.
8. Carlson K, Ljunghall S, Simonsson B, Smedmyr B Serum osteocalcin concentrations in patients with multiple myeloma - correlation with disease stage and survival. J Intern Med 1992;231:133-7.
9. Modi ND, Lentzsch S Bisphosphonates as antimyeloma drugs. Leukemia 2012;26:589-94.
10. Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012;119:5374-83.
11. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 1997;97:641-8.
12. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
13. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005;333:200-5.
14. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34.
15. Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008;32:1661-8.
16. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3.
17. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O Bone markers in multiple myeloma. Eur J Cancer 2006;42:1544-53.
18. Ozaki S, Tanaka O, Fujii S, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007;86:180-5.
19. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.
20. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009;84:6-14.
21. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-8.
22. Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504.
23. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S, Zhao M, Mundy GR Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007;139:434-8.
24. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008;142:492-4.
25. Ng AC, Kumar SK, Rajkumar SV, Drake MT Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009;84:397-400.
26. Laroche M, Lemaire O, Attal M Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. Eur J Haematol 2010;85:65-7.
27. Pittenger MF Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 2008;449:27-44.
28. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007;138:446-58.
29. Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305-12.
30. Schinke T, Schilling AF, Baranowsky A, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 2009;15:674-81.
31. Piek E, Sleumer LS, van Someren EP, et al. Osteo-transcriptomics of human mesenchymal stem cells: accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis. Bone 2010;46:613-27.
32. van Driel M, Koedam M, Buurman CJ, Roelse M, Weyts F, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP Evidence that both 1alpha, 25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 2006;99:922-35.
33. Goltzman D Vitamin D action: lessons learned from genetic mouse models. Ann N Y Acad Sci 2010;1192:145-52.
34. St-Arnaud R The direct role of vitamin D on bone homeostasis. Arch Biochem Biophys 2008;473:225-30.
35. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-8.
36. Lund T, Soe K, Abildgaard N, Garnero P, Pedersen PT, Ormstrup T, Delaisse JM, Plesner T First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 2010;85:290-9.
37. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010;21:1561-2.
38. Zangari M, Yaccoby S, Pappas L, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011;96:333-6.
39. Qiang YW, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009;113:4319-30.
40. Peleg S, Nguyen CV The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasome-mediated degradation. J Cell Biochem 2010;110:926-34.
41. Masuyama H, MacDonald PN Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J Cell Biochem 1998;71:429-40.
42. Diamond T, Golombick T, Manoharan A Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol 2010;85:302-3.